一位60多岁的男子患有免疫缺陷和肝炎
Caroline Hvitmyhr1, Kristin Fjeldstad Enga2, Joakim Øverbø3
1Medisinsk avdeling, Ringerike sykehus, Vestre Viken.
概括
免疫功能低下患者肝酶升高可能源于各种感染. 核酸检测对于诊断肝炎E病毒 (HEV) 在这个人群中至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 肝酶升高有多种原因,包括有毒性,传染性,瘤性和自身免疫性疾病.
- 免疫功能低下的患者具有更广泛的传染性肝炎病原体谱,免疫反应,复杂的诊断.
研究的目的:
- 要突出肝炎的诊断挑战在免疫功能低下的患者.
- 强调在风险人群中针对E型肝炎病毒 (HEV) 特定诊断方法的重要性.
主要方法:
- 一个为多发性骨髓瘤接受CAR-T治疗的患者的案例介绍.
- 讨论感染性肝炎的诊断策略在免疫受损的个体.
主要成果:
- 肝炎E是一种未被确诊的感染,在挪威可以感染.
- 在免疫功能低下的患者中,血清检测HEV可能不可靠.
结论:
- 免疫功能低下的患者患慢性肝炎E的风险增加.
- 核酸检测HEV RNA是建议的HEV在免疫受损患者的首要诊断方法.
相关概念视频
Immunodeficiency Diseases
2.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System
6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Hepatic Drug Excretion: Influencing Factors
599
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
599
Hepatic Drug Clearance: Role of Transporters
311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311


